Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Lizza E. L. Hendriks, Anita J. W. M. Brouns, Mohammad Amini, Wilma Uyterlinde, Robin Wijsman, Jan Bussink, Bonne Biesma, S. Bing Oei, Jos A. Stigt, Gerben P. Bootsma, Jose S. A. Belderbos, Dirk K. M. De Ruysscher, Michel M. Van den Heuvel, Anne-Marie C. Dingemans

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)68-75
JournalLung Cancer
Volume101
DOIs
Publication statusPublished - Nov 2016

Keywords

  • NSCLC
  • Stage III
  • Chemoradiation
  • Chemotherapy
  • Symptomatic brain metastases

Cite this

Hendriks, L. E. L., Brouns, A. J. W. M., Amini, M., Uyterlinde, W., Wijsman, R., Bussink, J., Biesma, B., Oei, S. B., Stigt, J. A., Bootsma, G. P., Belderbos, J. S. A., De Ruysscher, D. K. M., Van den Heuvel, M. M., & Dingemans, A-M. C. (2016). Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter? Lung Cancer, 101, 68-75. https://doi.org/10.1016/j.lungcan.2016.09.008